GHK-Cu — Research Overview
Chemical Name: Glycyl-L-histidyl-L-lysine copper (II) complex Also Known As: GHK-Cu, Copper peptide, Copper tripeptide, GHK copper Sequence: Gly-His-Lys complexed with copper (II) ion Molecular Weight: Approximately 340 daltons as the free tripeptide, 403 daltons as the copper complex Discovery: First isolated from human plasma albumin fraction in 1973 by Dr. Loren Pickart at the University of California San Francisco Endogenous Distribution: Present in human plasma, saliva, and urine. Plasma concentrations decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 — a decline of more than 60% over four decades. Category: Endogenous copper-binding tripeptide / tissue remodeling and wound healing research peptide
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is GHK-Cu?
GHK-Cu is a naturally occurring copper-binding tripeptide first isolated from the albumin fraction of human blood plasma in 1973 by Dr. Loren Pickart during graduate research at the University of California San Francisco. The original observation that prompted its isolation was that plasma from young donors restored normal protein synthesis patterns to liver cells from older donors — suggesting that some circulating factor in young blood carried regenerative signaling information. That factor was identified as the glycyl-L-histidyl-L-lysine tripeptide, and subsequent work established that it operates primarily in complex with copper (II) ions.
GHK-Cu has since become one of the most extensively characterized small endogenous peptides in the biomedical literature, with research spanning more than five decades across wound healing, skin biology, connective tissue remodeling, lung physiology, neuroprotection, antioxidant biology, and gene expression regulation. Unlike many research peptides that are fully synthetic with no endogenous counterpart, GHK-Cu is a physiological molecule whose natural decline with age has been directly linked to reduced tissue repair capacity, skin integrity, and regenerative potential in the published research.
The tripeptide sequence GHK appears naturally in the alpha-2(I) chain of type I collagen and can be liberated by proteases at sites of tissue injury, suggesting that GHK-Cu functions as an endogenous damage signal — a molecular marker of tissue disruption that mobilizes repair processes. It is also found within the extracellular matrix protein SPARC (secreted protein acidic and rich in cysteine), which is expressed abundantly in tissues undergoing rapid remodeling and which releases GHK-containing peptides upon proteolytic cleavage at injury sites.
An Important Clarification on Reconstitution
GHK-Cu is a copper-peptide complex. Unlike many peptides on this site, GHK-Cu requires bacteriostatic water as the sole reconstitution solvent. Acetic acid is not appropriate for GHK-Cu reconstitution because GHK-Cu is a pH-sensitive copper complex that is most stable at neutral to slightly alkaline pH. Acidic environments risk copper dissociation from the peptide, which would destroy the biological activity of the complex. GHK-Cu is highly water-soluble and dissolves readily in bacteriostatic water without requiring any acidic solvents.
Mechanism of Action
GHK-Cu exerts its biological effects through several interconnected mechanisms that have been characterized across decades of published research.
Extracellular matrix remodeling — dual collagen regulation: GHK-Cu simultaneously stimulates the synthesis of collagen and glycosaminoglycans while also modulating the activity of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). This dual regulation — promoting both new matrix production and controlled matrix degradation — is characteristic of healthy tissue remodeling rather than simple fibrosis or scar formation. At nanomolar concentrations GHK-Cu increases production of collagen types I and III, elastin, dermatan sulfate, chondroitin sulfate, and the small proteoglycan decorin.
Copper-dependent enzyme activation: The copper (II) ion in GHK-Cu activates copper-dependent enzymes including lysyl oxidase and lysyl hydroxylase, which are responsible for the crosslinking and hydroxylation of collagen and elastin fibers. This enzymatic activation is essential for structural integrity of newly synthesized connective tissue and distinguishes GHK-Cu from peptides that stimulate collagen gene expression without addressing the post-translational modification steps required for functional collagen assembly.
Cell recruitment and angiogenesis: GHK-Cu acts as a chemoattractant for monocytes, macrophages, and mast cells at sites of injury, orchestrating the immune phase of wound healing. It also increases the expression of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), promoting angiogenesis — the formation of new blood vessels required to restore blood supply to healing tissue.
Nerve outgrowth stimulation: GHK-Cu has been demonstrated to stimulate nerve outgrowth and increase production of nerve growth factor (NGF) and the neurotrophins NT-3 and NT-4 in nerve regeneration models.
Antioxidant activity: GHK-Cu inhibits lipid peroxidation by binding to ferritin channels involved in iron release, physically preventing the release of ferrous iron (Fe II) that drives Fenton chemistry and free radical cascades in damaged tissues. It also quenches specific toxic products of lipid peroxidation including 4-hydroxynonenal and acrolein.
Gene expression modulation at scale: Analysis using the Broad Institute’s Connectivity Map has identified GHK as capable of upregulating and downregulating at least 4,000 human genes — a scale of transcriptional influence that is unusual for a molecule of its size. This includes 47 DNA repair genes stimulated and broad effects on genes governing inflammation, tissue remodeling, cell cycle regulation, antioxidant response, and proteasome function.
NFkB suppression: GHK-Cu suppresses nuclear factor kappa B (NFkB), a master regulator of pro-inflammatory signaling, contributing to its anti-inflammatory profile without eliminating the acute inflammatory response needed for normal wound healing.
Published Research
Study 1 — Foundational: Isolation and Identification of GHK from Human Plasma
Authors: Pickart L, Thayer L, Thaler MM Year: 1973 Journal: Biochemical and Biophysical Research Communications Full text referenced via: https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
This was the original discovery study in which GHK was isolated as the active component from human plasma albumin fraction that restored youthful protein synthesis patterns to aging liver cells. The tripeptide was identified, its structure was characterized, and its biological activity as a growth-modulating plasma factor was established. This 1973 publication initiated more than five decades of subsequent research into the biological properties of GHK and GHK-Cu.
Study 2 — Collagen and Glycosaminoglycan Synthesis in Wound Tissue
Authors: Maquart FX, Bellon G, Pasco S, Monboisse JC et al. Year: 1993 and subsequent work Journal: Journal of Investigative Dermatology and related publications Referenced via: https://www.sciencedirect.com/science/article/pii/S0022202X1541067X
This foundational series of studies by researchers at the University of Reims established quantitative evidence for GHK-Cu’s effects on extracellular matrix production in wound tissue. Wound chambers injected with 2.0 mg GHK-Cu twice weekly were compared to saline controls in rats.
GHK-Cu injections significantly increased collagen content of wound chambers at day 18 (396% of controls) and day 22 (538% of controls) compared to vehicle controls, both reaching statistical significance (P less than 0.05).
Glycosaminoglycan content measured by uronic acid was significantly increased at days 12, 18, and 22 (191%, 180%, and 179% of controls respectively, P less than 0.05).
Analysis of GAG species confirmed GHK-Cu selectively modulated the relative proportions of specific glycosaminoglycan chains including dermatan sulfate and chondroitin sulfate — components important for structural matrix integrity and cellular signaling.
This study group identified GHK-Cu as a potent activator of wound healing, confirming its chemotactic activity for monocytes, macrophages, and mast cells, and its stimulation of angiogenesis in vivo — all consistent with multi-phase wound healing coordination.
Study 3 — Comprehensive Review: Skin Regeneration and Multiple Cellular Pathways
Authors: Pickart L, Vasquez-Soltero JM, Margolina A Year: 2015 Journal: BioMed Research International (PMC) PMID: 26236730 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
This widely cited open-access review by Pickart and colleagues synthesizes the accumulated evidence on GHK-Cu across wound healing, skin regeneration, and gene expression biology.
GHK-Cu is present in human plasma, saliva, and urine but declines significantly with age from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60.
GHK-Cu stimulates both synthesis and breakdown of collagen and glycosaminoglycans and modulates the activity of both matrix metalloproteinases and their inhibitors — a dual regulatory role characteristic of healthy remodeling.
It restores replicative vitality to fibroblasts after radiation therapy, suggesting DNA repair and cellular protective functions beyond structural protein synthesis.
In cosmetic human studies, GHK-Cu has been found in placebo-controlled trials to tighten loose skin, improve elasticity, skin density, and firmness, reduce fine lines and wrinkles, reduce photodamage, and reduce hyperpigmentation.
GHK-Cu is capable of upregulating and downregulating at least 4,000 human genes using analysis through the Broad Institute’s Connectivity Map, including 47 DNA repair genes stimulated with only 5 suppressed.
Clinical applications demonstrating accelerated wound healing have been documented for skin, hair follicles, gastrointestinal tract, bony tissue, and foot pads of dogs, as well as systemic wound healing models in rats, mice, and pigs.
Study 4 — COPD Gene Expression Reversal: Independent Multi-Institutional Research
Authors: Campbell JD, McDonough JE, Zeskind JE et al. (Boston University, University of Groningen, University of British Columbia, University of Pennsylvania) Year: 2012 Journal: Genome Medicine PMID: 22937864 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4064320/
This multi-institutional collaborative study from four major universities represents one of the most significant independent confirmations of GHK’s biological activity, conducted by researchers with no apparent affiliation to the primary GHK research group. It examined gene expression patterns in lung tissue from COPD patients and used the Broad Institute’s Connectivity Map to identify compounds capable of reversing the disease-associated gene expression signature.
The researchers identified 127 genes whose expression levels were significantly associated with regional emphysema severity, confirmed across four cross-sectional studies of COPD. Genes involved in inflammation were upregulated in severe COPD, while genes involved in tissue remodeling and repair — particularly TGF-beta pathway genes, actin organization, and integrin signaling — were downregulated.
Using the Connectivity Map, GHK was identified as a compound capable of reversing the gene expression signature associated with emphysematous destruction, inducing expression patterns consistent with TGF-beta pathway activation.
Treatment of human lung fibroblasts from COPD patients with GHK at 10 nM recapitulated TGF-beta-induced gene expression patterns, led to organization of the actin cytoskeleton, and elevated expression of integrin beta-1.
Addition of GHK or TGF-beta restored collagen I contraction and remodeling by COPD-derived fibroblasts to levels comparable to fibroblasts from lungs of exsmokers without COPD.
The authors concluded that gene expression changes associated with regional emphysema severity can identify novel therapeutic opportunities and that additional studies examining the mechanisms by which GHK reverses the gene expression signature of emphysematous destruction are warranted.
This study is notable because it represents independent multi-institutional confirmation of GHK’s gene-modulating biological activity in a clinically relevant human tissue model, conducted entirely outside the primary GHK research group.
Study 5 — Regenerative and Protective Actions: Comprehensive Gene Data Review
Authors: Pickart L, Margolina A Year: 2018 Journal: International Journal of Molecular Sciences (PubMed) PMID: 29986520 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
This 2018 review integrates newer gene expression data with the accumulated biological evidence for GHK-Cu across multiple tissue types and disease models.
GHK stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, and supports the function of dermal fibroblasts. Tissue repair effects have been demonstrated for skin, lung connective tissue, bony tissue, liver, and stomach lining.
GHK-Cu at 0.01, 1, and 100 nM concentrations incubated with human adult dermal fibroblasts increased production of both elastin and collagen. Gene expression of MMP1 and MMP2 was increased at 0.01 nM. All concentrations increased TIMP1.
A randomized double-blind clinical trial of GHK-Cu encapsulated in nano-lipid carrier, applied twice daily for 8 weeks in female volunteers, produced a 31.6% reduction of wrinkle volume compared to the reference peptide Matrixyl 3000, and a 55.8% reduction of wrinkle volume and 32.8% reduction of wrinkle depth compared to control serum.
GHK-Cu improved healing of ischemic open wounds in rats, with faster healing, decreased concentrations of metalloproteinases 2 and 9, and decreased TNF-beta compared to vehicle alone.
GHK-Cu increased production of nerve growth factor and the neurotrophins NT-3 and NT-4 in nerve regeneration models, increased axon count, and promoted proliferation of Schwann cells.
The review identifies GHK as a safe, inexpensive, extensively studied compound with a wealth of positive and health-promoting effects in many tissues and systems, noting that developing and testing GHK-based products for internal use to support health of elderly populations represents a promising future direction.
Study 6 — Pulmonary Fibrosis Protection: TGF-beta/Smad Pathway
Authors: Ma WH, Li M, Ma HF et al. Year: 2020 Journal: Life Sciences (PubMed indexed) Referenced via PMC 6073405
This preclinical study examined the protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis in animal models, focusing on the mechanism of protection.
GHK-Cu provided protective effects in pulmonary fibrosis through anti-oxidative stress and anti-inflammation pathways, specifically by inhibiting epithelial-to-mesenchymal transition (EMT) and suppressing TGF-beta1/Smad2/3 signaling.
Reduced inflammatory cell infiltration and attenuated fibrosis progression were observed in GHK-treated animals compared to controls.
This study adds mechanistic detail to the COPD gene expression findings, identifying the TGF-beta/Smad2/3 pathway as a specific target of GHK-Cu’s lung-protective activity.
Additional Research Areas With Documented Evidence
The following additional biological activities of GHK-Cu have been documented in published preclinical and clinical research. Evidence quality varies across each area.
Anti-cancer gene modulation: Using the Broad Institute Connectivity Map, analysis found that GHK significantly increased expression of 84 cancer-inhibitory or growth-inhibitory genes. Separate research reported GHK reactivated apoptosis in human neuroblastoma and histiocytic lymphoma cell lines at 1 to 10 nanomolar while increasing replication of normal NIH3T3 fibroblast cells — suggesting selective pro-apoptotic activity in cancer cells without harm to normal cells. These findings require further investigation and have not been validated in human clinical trials.
Hair follicle stimulation: GHK-Cu has been documented to accelerate healing of hair follicles and is incorporated in commercial hair growth products, though formal human clinical trial data specifically for hair growth applications is limited.
Diabetic wound healing: Clinical evidence referenced in multiple published reviews suggests that GHK-Cu treatment significantly improved the healing of skin ulcers in diabetic patients, though the original clinical trial publications in this area are older and not all are readily accessible in English.
Antioxidant properties: GHK-Cu inhibits lipid peroxidation through ferritin iron sequestration at concentrations of 10 to 100 micromolar, and quenches specific toxic lipid peroxidation products including 4-hydroxynonenal and acrolein — compounds implicated in Alzheimer’s disease, neuropathy, and retinopathy pathogenesis.
An Important Note on the Research Landscape
Unlike DSIP or Epithalon, GHK-Cu’s research base benefits from substantial independent multi-institutional replication. The COPD gene expression study from Campbell et al. was conducted at four major American universities entirely independently of Pickart’s group and confirms GHK’s gene-modulating activity in human tissue. Multiple independent cosmetic clinical trials confirm the skin effects. The core wound healing findings have been replicated across multiple laboratories and species. This makes GHK-Cu one of the more robustly supported compounds in this research database from an independent replication standpoint.
The gene expression claims — particularly the assertion that GHK-Cu modulates more than 4,000 human genes — derive from bioinformatic analysis using the Broad Institute’s Connectivity Map rather than from direct experimental measurement of each gene individually. This is a legitimate and widely used research methodology but represents computational prediction rather than individual experimental confirmation of each gene interaction.
Current Research Status
GHK-Cu is not FDA-approved for any pharmaceutical indication. It is used extensively in cosmetic and topical skin care products where it is generally recognized as safe at concentrations used in cosmetics. It is not on the WADA Prohibited Substances List, making it one of the few research peptides that is not restricted in competitive sport contexts.
The following represent active areas of ongoing or future research interest:
Formal clinical trials for COPD lung protection following the gene expression findings from Campbell et al.
Standardized clinical trial data for injectable GHK-Cu in wound healing applications beyond animal and limited human pilot studies.
Cancer biology applications based on the gene expression and pro-apoptotic findings in tumor cell lines.
Oral or systemic delivery formulation development, which is currently limited by the peptide’s susceptibility to carboxypeptidase enzyme degradation in vivo.
Reconstitution Note
GHK-Cu is a copper-peptide complex. Bacteriostatic water is the only appropriate reconstitution solvent for GHK-Cu in laboratory research settings. GHK-Cu is a pH-sensitive compound — its copper binding is stable at neutral to slightly alkaline pH. Acidic solvents including acetic acid are not appropriate and risk copper dissociation from the peptide, which would compromise the biological activity of the complex. GHK-Cu dissolves readily in bacteriostatic water without requiring acidic solvents. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the GHK-Cu product page: https://roguecompounds.com/product/ghk-cu/